Rather than benchmarking the cost of pharmaceuticals to inflation rates—and finding it alarmingly high—stakeholders should be asking whether the value of medical innovation is rising faster than ...
Dara-Abasi Ita writes about trading and investing for Investopedia and Investing.com, and he is an editor at Lawverse magazine. He has written about financial topics, including private equity, asset ...
Examining whether negotiated prices align with value is one way of asking if CMS “got pricing right” and if the Medicare program is getting its money’s worth. A key question is whether the IPAY 2027 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results